• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用增殖信号抑制剂将移植患者的肾衰竭降至最低

[Minimize kidney failure in transplantation patients with proliferation signal inhibitors].

作者信息

Glowacki F, Dharancy S, Noël C, Hazzan M

机构信息

Pôle de Néphrologie, Hôpital Albert Calmette, CHRU de Lille, Bd du Pr Leclercq, 59037 Lille cedex, France.

出版信息

Gastroenterol Clin Biol. 2009 Nov;33 Suppl 4:S253-6. doi: 10.1016/S0399-8320(09)73162-8.

DOI:10.1016/S0399-8320(09)73162-8
PMID:20004331
Abstract

Chronic renal dysfunction is a multifactorial and frequent event after organ transplantation. The measurement or the estimation of glomerular filtration rate is essential to detect early progressive renal dysfunction. Proliferation signal inhibitors are nonnephrotoxic immunosuppressive drugs which may be useful to minimize calcineurin inhibitors-related side effects through a conversion strategy. Most studies in the setting of kidney transplantation showed improvement in glomerular filtration rate as high than conversion was early. Proliferation signal inhibitors may be included quickly in new immunosuppressive regimen for liver transplanted patients with chronic renal dysfunction.

摘要

慢性肾功能不全是器官移植后常见的多因素事件。肾小球滤过率的测量或估算对于早期发现进行性肾功能不全至关重要。增殖信号抑制剂是一种非肾毒性免疫抑制药物,通过转换策略可用于尽量减少钙调神经磷酸酶抑制剂相关的副作用。大多数肾移植相关研究表明,转换越早,肾小球滤过率改善越高。增殖信号抑制剂可迅速纳入慢性肾功能不全肝移植患者的新免疫抑制方案中。

相似文献

1
[Minimize kidney failure in transplantation patients with proliferation signal inhibitors].使用增殖信号抑制剂将移植患者的肾衰竭降至最低
Gastroenterol Clin Biol. 2009 Nov;33 Suppl 4:S253-6. doi: 10.1016/S0399-8320(09)73162-8.
2
[Side effects of proliferation signal inhibitors and their management].[增殖信号抑制剂的副作用及其管理]
Gastroenterol Clin Biol. 2009 Nov;33 Suppl 4:S268-74. doi: 10.1016/S0399-8320(09)73165-3.
3
Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.肝移植术后慢性肾功能不全患者由钙调磷酸酶抑制剂转换为依维莫司后肾功能的改善。
Liver Transpl. 2009 Dec;15(12):1792-7. doi: 10.1002/lt.21920.
4
Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.肝移植受者从钙调神经磷酸酶抑制剂转换为西罗莫司后,肾功能会有所改善。
Liver Transpl. 2003 Oct;9(10):1079-85. doi: 10.1053/jlts.2003.50183.
5
Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.肝移植中使用雷帕霉素哺乳动物靶点抑制剂药物进行挽救性免疫抑制
Transplant Proc. 2010 Mar;42(2):641-3. doi: 10.1016/j.transproceed.2010.02.011.
6
What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?关于从钙调神经磷酸酶抑制剂转换为西罗莫司,CONVERT试验究竟告诉了我们什么?
Transplantation. 2009 Jan 27;87(2):164-5. doi: 10.1097/TP.0b013e318192790f.
7
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.肾移植患者从钙调神经磷酸酶抑制剂转换为西罗莫司后出现移植肾功能障碍的长期结果。
Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. doi: 10.1093/ndt/gfh957. Epub 2005 Jun 28.
8
Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.在合并肾衰竭的初次心脏移植中使用增殖信号抑制剂避免使用钙调神经磷酸酶抑制剂。
J Heart Lung Transplant. 2008 Oct;27(10):1135-41. doi: 10.1016/j.healun.2008.07.020.
9
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.肾移植受者从钙调神经磷酸酶抑制剂转换为西罗莫司维持治疗:CONVERT试验的24个月疗效和安全性结果
Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.
10
A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.一项针对肾功能受损的肝移植受者从基于钙调神经磷酸酶抑制剂(CNI)转换为基于西罗莫司的免疫抑制方案的晚期转换的随机对照试验。
Liver Transpl. 2007 Dec;13(12):1694-702. doi: 10.1002/lt.21314.